Tegoprazan

Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a reversible, orally active and highly selective inhibitor of gastric H+/K+-ATPase. Tegoprazan inhibits gastric acid secretion and motility against porcine, canine and human H+/K+-ATPase with IC50 values ranging from 0.29-0.52 μM in vitro. Tegoprazan significantly improves colitis and enhances the intestinal epithelial barrier function in mice. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases[1][2][3].

Product Specifications

CAS Number

[942195-55-3]

Product Name Alternative

CJ-12420; RQ-00000004

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Na+/K+ ATPase; Potassium Channel; Proton Pump

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Tegoprazan.html

Concentration

10mM

Purity

99.76

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

FC1=CC(F)=C2[C@@H](OC3=CC(C(N(C)C)=O)=CC4=C3N=C(C)N4)CCOC2=C1

Molecular Formula

C20H19F2N3O3

Molecular Weight

387.38

Precautions

H302, H315, H319, H335

References & Citations

[2]Son M, et al. Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function[J]. Front Immunol. 2022 May 25;13:870817. |[3]Kim DK, et al. Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease[J]. J Pharmacol Exp Ther. 2019 Jun;369 (3) :318-327. |[1]Takahashi N, et al. Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility. J Pharmacol Exp Ther. 2018 Feb;364 (2) :275-286.